{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T18:25:52Z","timestamp":1777141552852,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Nomlabofusp is a cell penetrant peptide-based recombinant fusion protein designed to enter cells and deliver human frataxin into the mitochondria of adults and children with Friedreich\u2019s ataxia. In this article we present non-clinical studies evaluating the pharmacology of nomlabofusp, including in a murine striated muscle tissue frataxin knockout model of Friedreich\u2019s ataxia. We demonstrate that subcutaneous administration of nomlabofusp distributes in a dose-dependent manner to several organs including the dorsal root ganglion, heart, and skeletal muscle, which are known to be predominantly affected in Friedreich\u2019s ataxia, as well as to other tissues, including skin. Plasma nomlabofusp concentrations correlated with levels of human frataxin delivered by nomlabofusp into tissues, and the increases in frataxin were correlated amongst tissues, especially with skin. In the knockout mice, we show that the pharmacokinetics and processing of nomlabofusp were comparable with wild\u00a0type animals and that treatment with nomlabofusp halts the progression of cardiac dysfunction and significantly increased survival. Together, the findings from these non-clinical studies demonstrate that nomlabofusp exposure increases human frataxin in Friedreich\u2019s ataxia-relevant tissues and provide evidence of pharmacologic effects.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1208\/s12248-025-01093-y","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T17:39:56Z","timestamp":1750873196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics and Pharmacodynamics of Nomlabofusp in Non-clinical Studies of Friedreich\u2019s Ataxia"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6701-7710","authenticated-orcid":false,"given":"Flavia","family":"De Toni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3202-5447","authenticated-orcid":false,"given":"Vanessa","family":"Ragaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devin","family":"Schecter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik J.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-9304","authenticated-orcid":false,"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-3628","authenticated-orcid":false,"given":"R. Mark","family":"Payne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8756-3828","authenticated-orcid":false,"given":"Jean-Nicholas","family":"Mess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2680-1178","authenticated-orcid":false,"given":"Matthew G.","family":"Baile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne","family":"Clements-Egan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7224-1201","authenticated-orcid":false,"given":"Gopi","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"issue":"1","key":"1093_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/bmb\/ldx034","volume":"124","author":"A Cook","year":"2017","unstructured":"Cook A, Giunti P. Friedreich\u2019s ataxia: clinical features, pathogenesis and management. Br Med Bull. 2017;124(1):19\u201330. https:\/\/doi.org\/10.1093\/bmb\/ldx034.","journal-title":"Br Med Bull"},{"issue":"10","key":"1093_CR2","first-page":"1296","volume":"75","author":"M Pandolfo","year":"2008","unstructured":"Pandolfo M. Friedreich Ataxia. Arch Neurol. 2008;75(10):1296\u2013303.","journal-title":"Arch Neurol"},{"issue":"5","key":"1093_CR3","doi-asserted-by":"publisher","first-page":"e63958","DOI":"10.1371\/journal.pone.0063958","volume":"8","author":"HL Plasterer","year":"2013","unstructured":"Plasterer HL, Deutsch EC, Belmonte M, Egan E, Lynch DR, Rusche JR. Development of frataxin gene expression measures for the evaluation of experimental treatments in friedreich\u2019s ataxia. PLoS ONE. 2013;8(5):e63958. https:\/\/doi.org\/10.1371\/journal.pone.0063958.","journal-title":"PLoS ONE"},{"issue":"11","key":"1093_CR4","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/hmg\/6.11.1771","volume":"6","author":"V Campuzano","year":"1997","unstructured":"Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, Jiralerspong S, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Human Mol Gen. 1997;6(11):1771\u201380.","journal-title":"Human Mol Gen"},{"issue":"11","key":"1093_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0166-2236(96)20054-2","volume":"19","author":"TJ Gibson","year":"1996","unstructured":"Gibson TJ, Koonin EV, Musco G, Pastore A, Bork P. Friedreich\u2019s ataxia protein: phylogenetic evidence for mitochondrial dysfunction. Trends Neurosci. 1996;19(11):465\u20138. https:\/\/doi.org\/10.1016\/S0166-2236(96)20054-2.","journal-title":"Trends Neurosci"},{"issue":"7","key":"1093_CR6","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.3390\/antiox12071477","volume":"12","author":"E Goetzman","year":"2023","unstructured":"Goetzman E, Gong Z, Zhang B, Muzumdar R. Complex II biology in aging, health, and disease. Antioxidants (Basel). 2023;12(7):1477. https:\/\/doi.org\/10.3390\/antiox12071477.","journal-title":"Antioxidants (Basel)."},{"issue":"15","key":"1093_CR7","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1093\/hmg\/ddi214","volume":"14","author":"P Gonzalez-Cabo","year":"2005","unstructured":"Gonzalez-Cabo P, Vazquez-Manrique RP, Garcia-Gimeno MA, Sanz P, Palau F. Frataxin interacts functionally with mitochondrial electron transport chain proteins. Human Mol Gen. 2005;14(15):2091\u20138. https:\/\/doi.org\/10.1093\/hmg\/ddi214.","journal-title":"Human Mol Gen"},{"issue":"1","key":"1093_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/iub.577","volume":"64","author":"MV Busi","year":"2012","unstructured":"Busi MV, Gomez-Casati DF. Exploring frataxin function. IUBMB Life. 2012;64(1):56\u201363. https:\/\/doi.org\/10.1002\/iub.577.","journal-title":"IUBMB Life"},{"issue":"8","key":"1093_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/hmg\/9.8.1219","volume":"9","author":"M Cossee","year":"2000","unstructured":"Cossee M, Puccio H, Gansmuller A, Koutnikova H, Dierich A, LeMeur M, et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet. 2000;9(8):1219\u201326. https:\/\/doi.org\/10.1093\/hmg\/9.8.1219.","journal-title":"Hum Mol Genet"},{"issue":"Suppl 1","key":"1093_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jnc.12219","volume":"126","author":"M Perdomini","year":"2013","unstructured":"Perdomini M, Hick A, Puccio H, Pook MA. Animal and cellular models of Friedreich ataxia. J Neurochem. 2013;126(Suppl 1):65\u201379. https:\/\/doi.org\/10.1111\/jnc.12219.","journal-title":"J Neurochem"},{"issue":"7","key":"1093_CR11","doi-asserted-by":"publisher","first-page":"119809","DOI":"10.1016\/j.bbamcr.2024.119809","volume":"1871","author":"V Mosbach","year":"2024","unstructured":"Mosbach V, Puccio H. A multiple animal and cellular models approach to study frataxin deficiency in Friedreich Ataxia. Biochim Biophys Acta Mol Cell Res. 2024;1871(7):119809. https:\/\/doi.org\/10.1016\/j.bbamcr.2024.119809.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1093_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/84818","volume":"27","author":"H Puccio","year":"2001","unstructured":"Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, Melki J, et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Gen. 2001;27:181\u20136.","journal-title":"Nat Gen"},{"issue":"5","key":"1093_CR13","doi-asserted-by":"publisher","first-page":"e0178354","DOI":"10.1371\/journal.pone.0178354","volume":"12","author":"AR Stram","year":"2017","unstructured":"Stram AR, Wagner GR, Fogler BD, Pride PM, Hirschey MD, Payne RM. Progressive mitochondrial protein lysine acetylation and heart failure in a model of Friedreich\u2019s ataxia cardiomyopathy. PLoS ONE. 2017;12(5):e0178354. https:\/\/doi.org\/10.1371\/journal.pone.0178354.","journal-title":"PLoS ONE"},{"key":"1093_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/ng1097-215","volume":"17","author":"A Rotig","year":"1997","unstructured":"Rotig A, De Lonlay P, Chretien D, Foury F, Koenig M, Sidi D, et al. Aconitase and mitochondrial iron\u2013sulphur protein deficiency in Friedreich ataxia. Nat Gen. 1997;17:215\u20137.","journal-title":"Nat Gen"},{"issue":"2","key":"1093_CR15","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/jcmm.13365","volume":"22","author":"E Britti","year":"2018","unstructured":"Britti E, Delaspre F, Feldman A, Osborne M, Greif H, Tamarit J, et al. Frataxin-deficient neurons and mice models of Friedreich ataxia are improved by TAT-MTScs-FXN treatment. J Cell Mol Med. 2018;22(2):834\u201348. https:\/\/doi.org\/10.1111\/jcmm.13365.","journal-title":"J Cell Mol Med"},{"key":"1093_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.omtm.2022.02.002","volume":"24","author":"C Huichalaf","year":"2022","unstructured":"Huichalaf C, Perfitt TL, Kuperman A, Gooch R, Kovi RC, Brenneman KA, et al. In vivo overexpression of frataxin causes toxicity mediated by iron-sulfur cluster deficiency. Mol Ther Methods Clin Dev. 2022;24:367\u201378. https:\/\/doi.org\/10.1016\/j.omtm.2022.02.002.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"5","key":"1093_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nm.3510","volume":"20","author":"M Perdomini","year":"2014","unstructured":"Perdomini M, Belbellaa B, Monassier L, Reutenauer L, Messaddeq N, Cartier N, et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich\u2019s ataxia. Nat Med. 2014;20(5):542\u20137. https:\/\/doi.org\/10.1038\/nm.3510.","journal-title":"Nat Med"},{"issue":"25","key":"1093_CR18","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1074\/jbc.272.25.16010","volume":"272","author":"E Vives","year":"1997","unstructured":"Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 1997;272(25):16010\u20137. https:\/\/doi.org\/10.1074\/jbc.272.25.16010.","journal-title":"J Biol Chem"},{"issue":"3","key":"1093_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1208\/s12248-025-01054-5","volume":"27","author":"MG Baile","year":"2025","unstructured":"Baile MG, Jones J, Sahr N, Shankar G. Nomlabofusp, a fusion protein of human frataxin and a cell penetrant peptide, delivers mature and functional frataxin into mitochondria. AAPS J. 2025;27(3):68. https:\/\/doi.org\/10.1208\/s12248-025-01054-5.","journal-title":"AAPS J"},{"issue":"3","key":"1093_CR20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/acn3.51971","volume":"11","author":"R Clayton","year":"2024","unstructured":"Clayton R, Galas T, Scherer N, Farmer J, Ruiz N, Hamdani M, et al. Safety, pharmacokinetics, and pharmacodynamics of nomlabofusp (CTI-1601) in Friedreich\u2019s ataxia. Ann Clin Transl Neurol. 2024;11(3):540\u201353. https:\/\/doi.org\/10.1002\/acn3.51971.","journal-title":"Ann Clin Transl Neurol"},{"key":"1093_CR21","volume-title":"Effect of nomlabofusp administration on tissue frataxin levels, plasma lipid profiles, and gene expression in patients with Friedreich\u2019s ataxia","author":"N Scherer","year":"2024","unstructured":"Scherer N, Clements-Egan A, Hamdani M, Shenouda M, Forest A, Des Rosiers C, et al. Effect of nomlabofusp administration on tissue frataxin levels, plasma lipid profiles, and gene expression in patients with Friedreich\u2019s ataxia. London: International Congress for Ataxia Research; 2024."},{"issue":"2","key":"1093_CR22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nprot.2006.478","volume":"2","author":"C Frezza","year":"2007","unstructured":"Frezza C, Cipolat S, Scorrano L. Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts. Nat Protoc. 2007;2(2):287\u201395. https:\/\/doi.org\/10.1038\/nprot.2006.478.","journal-title":"Nat Protoc"},{"issue":"6","key":"1093_CR23","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/s1525-0016(03)00130-8","volume":"7","author":"V Del Gaizo","year":"2003","unstructured":"Del Gaizo V, Payne RM. A novel TAT\u2013Mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Mol Ther. 2003;7(6):720\u201330. https:\/\/doi.org\/10.1016\/s1525-0016(03)00130-8.","journal-title":"Mol Ther"},{"issue":"11","key":"1093_CR24","doi-asserted-by":"publisher","first-page":"9803","DOI":"10.1074\/jbc.M307167200","volume":"279","author":"JA MacKenzie","year":"2004","unstructured":"MacKenzie JA, Payne RM. Ribosomes specifically bind to mammalian mitochondria via protease-sensitive proteins on the outer membrane. J Biol Chem. 2004;279(11):9803\u201310. https:\/\/doi.org\/10.1074\/jbc.M307167200.","journal-title":"J Biol Chem"},{"key":"1093_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0065-7743(10)45004-6","volume-title":"Annual Reports in Medicinal Chemistry","author":"CL Shaffer","year":"2010","unstructured":"Shaffer CL. Chapter 4 - Defining neuropharmacokinetic parameters in CNS drug discovery to determine cross-species pharmacologic exposure-response relationships. In: Macor JE, editor. Annual Reports in Medicinal Chemistry. Academic Press; 2010. p. 55\u201370."},{"issue":"2","key":"1093_CR26","doi-asserted-by":"publisher","first-page":"H357","DOI":"10.1152\/ajpheart.00496.2023","volume":"326","author":"TL Perfitt","year":"2024","unstructured":"Perfitt TL, Huichalaf C, Gooch R, Kuperman A, Ahn Y, Chen X, et al. A modified mouse model of Friedreich\u2019s ataxia with conditional Fxn allele homozygosity delays onset of cardiomyopathy. Am J Physiol Heart Circ Physiol. 2024;326(2):H357\u201369. https:\/\/doi.org\/10.1152\/ajpheart.00496.2023.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1093_CR27","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.31.015255","author":"B Belbellaa","year":"2020","unstructured":"Belbellaa B, Reutenauer L, Messaddeq N, Monassier L, Puccio H. High levels of frataxin overexpression leads to mitochondrial and cardiac toxicity in mouse models. BioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.31.015255.","journal-title":"BioRxiv"},{"issue":"3","key":"1093_CR28","doi-asserted-by":"publisher","first-page":"e17627","DOI":"10.1371\/journal.pone.0017627","volume":"6","author":"F Sacca","year":"2011","unstructured":"Sacca F, Puorro G, Antenora A, Marsili A, Denaro A, Piro R, et al. A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design. PLoS ONE. 2011;6(3):e17627. https:\/\/doi.org\/10.1371\/journal.pone.0017627.","journal-title":"PLoS ONE"},{"issue":"4","key":"1093_CR29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ymgme.2008.03.019","volume":"94","author":"JH Willis","year":"2008","unstructured":"Willis JH, Isaya G, Gakh O, Capaldi RA, Marusich MF. Lateral-flow immunoassay for the frataxin protein in Friedreich\u2019s ataxia patients and carriers. Mol Genet Metab. 2008;94(4):491\u20137. https:\/\/doi.org\/10.1016\/j.ymgme.2008.03.019.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"1093_CR30","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.ajpath.2013.05.032","volume":"183","author":"ML Huang","year":"2013","unstructured":"Huang ML, Sivagurunathan S, Ting S, Jansson PJ, Austin CJ, Kelly M, et al. Molecular and functional alterations in a mouse cardiac model of Friedreich ataxia: activation of the integrated stress response, eIF2alpha phosphorylation, and the induction of downstream targets. Am J Pathol. 2013;183(3):745\u201357. https:\/\/doi.org\/10.1016\/j.ajpath.2013.05.032.","journal-title":"Am J Pathol"},{"issue":"6","key":"1093_CR31","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/hmg\/ddr554","volume":"21","author":"PM Vyas","year":"2012","unstructured":"Vyas PM, Tomamichel WJ, Pride PM, Babbey CM, Wang Q, Mercier J, et al. A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich\u2019s ataxia mouse model. Hum Mol Genet. 2012;21(6):1230\u201347. https:\/\/doi.org\/10.1093\/hmg\/ddr554.","journal-title":"Hum Mol Genet"},{"issue":"13-14","key":"1093_CR32","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1089\/hum.2023.020","volume":"34","author":"C Munoz-Zuluaga","year":"2023","unstructured":"Munoz-Zuluaga C, Gertz M, Yost-Bido M, Greco A, Gorman N, Chen A, et al. Identification of safe and effective intravenous dose of AAVrh10hFXN to treat the cardiac manifestations of friedreich\u2019s ataxia. Hum Gene Ther. 2023;34(13\u201314):605\u201315. https:\/\/doi.org\/10.1089\/hum.2023.020.","journal-title":"Hum Gene Ther."},{"key":"1093_CR33","volume-title":"Prediction of tissue frataxin levels with long term administration of nomlabofusp in adults with Friedreich\u2019s ataxia using modeling and simulations","author":"F De Toni","year":"2024","unstructured":"De Toni F, Scherer N, Schapiro E, Shenouda M, Hamdani M, Shankar G, et al. Prediction of tissue frataxin levels with long term administration of nomlabofusp in adults with Friedreich\u2019s ataxia using modeling and simulations. London: International Congress for Ataxia Research; 2024."},{"key":"1093_CR34","doi-asserted-by":"publisher","first-page":"114107","DOI":"10.1016\/j.bbr.2022.114107","volume":"436","author":"C Gerard","year":"2023","unstructured":"Gerard C, Archambault AF, Bouchard C, Tremblay JP. A promising mouse model for Friedreich Ataxia progressing like human patients. Behav Brain Res. 2023;436:114107. https:\/\/doi.org\/10.1016\/j.bbr.2022.114107.","journal-title":"Behav Brain Res"},{"key":"1093_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.006","author":"F Piguet","year":"2018","unstructured":"Piguet F, de Montigny C, Vaucamps N, Reutenauer L, Eisenmann A, Puccio H. Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of friedreich ataxia. Mol Ther. 2018. https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.006.","journal-title":"Mol Ther"},{"issue":"8","key":"1093_CR36","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.3390\/genes14081654","volume":"14","author":"C Bouchard","year":"2023","unstructured":"Bouchard C, Gerard C, Yanyabe SG, Majeau N, Aloui M, Buisson G, et al. Finding an appropriate mouse model to study the impact of a treatment for friedreich ataxia on the behavioral phenotype. Genes (Basel). 2023;14(8):1654. https:\/\/doi.org\/10.3390\/genes14081654.","journal-title":"Genes (Basel)."},{"issue":"10","key":"1093_CR37","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1002\/mds.23789","volume":"26","author":"W Nachbauer","year":"2011","unstructured":"Nachbauer W, Wanschitz J, Steinkellner H, Eigentler A, Sturm B, Hufler K, et al. Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia. Mov Disord. 2011;26(10):1935\u20138. https:\/\/doi.org\/10.1002\/mds.23789.","journal-title":"Mov Disord"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01093-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01093-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01093-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:51:37Z","timestamp":1757199097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01093-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01093-y","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FDT, VR, MGB, ACE, and GS are employed by Larimar Therapeutics, Inc. (\u201cLarimar\u201d) and they and\/or their immediate family members may hold company stock or stock options. ASM (Johnson & Johnson Innovative Medicine, Spring House, PA, USA) and DS (Instadiagnostics, Philadelphia, PA, USA) were employees of Larimar at the time this work was conducted. RMP is a paid consultant to Larimar and owns stock in this company. GS chairs the Larimar Scientific Advisory Board. EG, EJW, and XX declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"112"}}